Mediar Therapeutics
Clinical trials sponsored by Mediar Therapeutics, explained in plain language.
-
New hope for scleroderma patients as experimental drug enters mid-stage trial
Disease control Recruiting nowThis study tests whether the experimental drug MTX-474 can safely reduce skin thickening in people with diffuse cutaneous systemic sclerosis, a rare autoimmune disease that causes hard, tight skin and can damage internal organs. About 85 adults with early-stage disease will recei…
Phase: PHASE2 • Sponsor: Mediar Therapeutics • Aim: Disease control
Last updated May 26, 2026 07:32 UTC
-
New hope for IPF: experimental drug MTX-463 enters Mid-Stage trial
Disease control Recruiting nowThis study tests whether the experimental drug MTX-463 can help people with idiopathic pulmonary fibrosis (IPF), a serious lung disease that causes scarring and makes breathing hard. About 164 adults aged 40 and older with IPF will receive either MTX-463 or a placebo for 24 weeks…
Phase: PHASE2 • Sponsor: Mediar Therapeutics • Aim: Disease control
Last updated May 18, 2026 12:02 UTC
-
New drug MTX-439 enters first human safety tests for diabetic kidney disease
Knowledge-focused Recruiting nowThis early-phase study tests the safety of a new drug called MTX-439 in healthy adults and people with diabetic kidney disease. Researchers will give single or multiple doses to see how the body handles the drug and what side effects occur. The study does not aim to treat the dis…
Phase: PHASE1 • Sponsor: Mediar Therapeutics • Aim: Knowledge-focused
Last updated May 22, 2026 13:52 UTC